BioAtla, Inc. Common Stock
$3.360
USD
Last updated on --.
24h volume113.46K
24h highest3.5900 USD
24h lowest3.3000 USD
24h Price movement+0.90%
BCAB recent prices
24 Hours
+0.90%+$0.03
30 days
-30.58%-$1.480
60 days
-24.32%-$1.080
90 days
-64.46%-$6.095
Key data
Previous close3.3300 USD
Market cap6.51M USD
Volume113.46K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-30.5500 USD
Net income (FY)-50.62M USD
Revenue (FY)2.00M USD
Last report dateMay 15, 2026
About BioAtla, Inc. Common Stock
HeadquartersSAN DIEGO
Employees (FY)41.00
Revenue per employee (FY)48.78K USD
Net income per employee (FY)-1.23M USD
Listed onNasdaq
BCAB conversion tables
 |  |
|---|---|
| 0.5 BCAB | 1.680 USD |
| 1 BCAB | 3.360 USD |
| 5 BCAB | 16.8 USD |
| 10 BCAB | 33.6 USD |
| |
|---|---|
| 0.5 USD | 0.14881 BCAB |
| 1 USD | 0.29762 BCAB |
| 5 USD | 1.488 BCAB |
| 10 USD | 2.976 BCAB |
More to explore
Trending stock
Trending stock PERP
Trending stock token
FAQ
BCAB is trading at $3.360, +0.90% over the last 24 hours. Track live moves on the price chart at the top of this page.
The BCAB stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. BCAB is currently trading at $3.360, +0.90% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on BCAB price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. BCAB's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from BCAB; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against BCAB's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
BioAtla, Inc. Common Stock's market cap is currently 6.51M USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume113.46K
24h highest3.5900 USD
24h lowest3.3000 USD
24h Price movement+0.90%
Start trade with BCAB Perpetual
Sign up to trade